undamentalytics Newsletter
Sign in

Cue Biopharma, Inc. cash flow statement

In fiscal 2025, Cue Biopharma, Inc.'s operations generated −$21.7m of cash; it spent $177,000 on capital projects, leaving free cash flow of −$21.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−26−31−32−39−42−40−36−22−50
Depreciation and amortisation111111011
Stock-based pay771012987526
Capital spending201100000
Free cash flow−28−31−33−40−42−40−36−22−50
Free cash flow after stock pay−35−37−44−51−51−48−43−27−76
Share buybacks—00100———
Shares issued—495702301128—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CUE vs ZYMECUE vs NBTXCUE vs FHTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cue Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cue Biopharma, Inc.